Trials / Completed
CompletedNCT05970978
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112. The study will enroll 160 participants who were diagnosed with plaque psoriasis. The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | regular treatment | IBI112 200mg s.c. at week 0, 12, 24 and 36. |
| DRUG | Intensive treatment | IBI112 200mg s.c. at week 0, 4, 8, 20 and 32. |
Timeline
- Start date
- 2023-08-28
- Primary completion
- 2024-07-19
- Completion
- 2025-01-26
- First posted
- 2023-08-02
- Last updated
- 2025-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05970978. Inclusion in this directory is not an endorsement.